시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 레녹스 가스토 증후군(LGS) 치료제 시장 보고서(2025년)
Lennox-Gastaut Syndrome Drug Global Market Report 2025
상품코드 : 1760590
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,222,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,993,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,765,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

레녹스 가스토 증후군(LGS) 치료제 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 예측 기간 동안의 성장은 정밀 의학에 대한 강조 증가, 신흥 시장의 의료 인프라 확장, 임상 시험 건수 증가, 개선된 보험 상환 정책, 희귀 질환 연구 개발 투자 증대, 그리고 유전자 검사를 통한 진단율 상승과 같은 요인에 기인합니다. 예측 기간에 있어서의 주요 동향으로서는 진단 기술의 혁신, 드러그 딜리버리 기술의 발전, 바이오마커 동정의 진전, 신약에 있어서의 인공지능의 활용, 차세대 시퀀서 기술의 개발, 표적 유전자 치료의 창출 등을 들 수 있습니다.

소아 간질을 중시하는 경향이 강해지고 있어 향후 수년간에 레녹스 가스토 증후군(LGS) 치료제 시장의 성장을 크게 끌어 올 것으로 예측됩니다. 소아 뇌전증은 신생아 및 유아 뇌 손상의 증가율로 인해 유병률이 증가하는 등 어린이에게 반복적인 발작이 나타나는 신경학적 질환으로, 유아기에 뇌전증이 발생할 수 있습니다. 간질을 가진 소아의 발달 지체를 막기 위해 필수적입니다. 2022년에 18세 이상의 미국 성인 약 290만명이 활동성 간질을 앓고, 미국의 성인 인구의 약 1%를 차지한다고 보고했습니다.

레녹스 가스토 증후군(LGS) 치료제 시장의 주요 기업은 규제 당국의 지지를 얻고 시장 독점권을 확보하며이 희귀하고 심각한 질병에 대한 치료의 상업화를 촉진하기 위해 희귀 질병 의약품 지정의 진전에 점점 주력하고 있습니다. 희소질환용 의약품의 지정은 특정 지역에서 20만명 미만만을 앓고 있는 희소질환이나 질환을 위해 개발된 의약품에 FDA 등의 규제 당국이 부여하는 특별한 상태입니다. 예를 들어 미국 제약회사 마리나스 퍼머슈티컬즈 잉크는 2023년 3월 레녹스 가스트 증후군(LGS) 치료제로 가낙솔론에게 FDA로부터 희소질병용 의약품 지정(ODD)을 받았다고 발표했습니다. LGS는 소아기에 발병하여 난치성 간질 발작과 신경 발달 장애를 특징으로 하는 심각한 간질입니다. 이 지정은 승인 후 시장 독점권, FDA 신청 비용 면제, 적격한 임상시험에 대한 세액 공제 등의 이점을 포함합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장의 거시경제 시나리오: 금리, 인플레이션, 지정학, 무역 전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 : 경쟁 벤치마킹 대시보드

제33장 주요 기업 합병 및 인수(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가·부문과 전략

제36장 부록

SHW
영문 목차

영문목차

Lennox-Gastaut syndrome drug refers to medication specifically developed or prescribed to manage the seizures and other symptoms associated with this severe form of epilepsy. These medications work by adjusting brain chemistry to control irregular electrical activity, thus reducing the frequency and severity of seizures.

The main types of Lennox-Gastaut syndrome drugs include central nervous system depressants, anticonvulsants, perampanel, cannabidiol, neural regeneration peptide 2945, and others. Central nervous system depressants are drugs that lower brain activity, helping with seizure control and promoting relaxation. They can be administered orally, via injection, intranasally, or topically, and are used for long-term management, acute seizure treatment, adjunctive therapy, and as rescue medications. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used in settings such as hospitals, clinics, home care, specialized epilepsy centers, and pharmaceutical retail outlets.

The lennox-gastaut syndrome drug market research report is one of a series of new reports from The Business Research Company that provides lennox-gastaut syndrome drug market statistics, including lennox-gastaut syndrome drug industry global market size, regional shares, competitors with an lennox-gastaut syndrome drug market share, detailed lennox-gastaut syndrome drug market segments, market trends and opportunities, and any further data you may need to thrive in the lennox-gastaut syndrome drug industry. The lennox-gastaut syndrome drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lennox-gastaut syndrome drug market size has grown strongly in recent years. It will grow from $1.30 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be credited to a rise in awareness of rare epileptic disorders, an increasing prevalence of pediatric epilepsy, better access to healthcare, enhanced investment in neurology research, and incentives provided by orphan drug designations.

The lennox-gastaut syndrome drug market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to a greater emphasis on precision medicine, the expansion of healthcare infrastructure in emerging markets, a higher number of clinical trials, improved reimbursement policies, increased investment in research and development for rare diseases, and rising diagnosis rates through genetic testing. Key trends in the forecast period include innovations in diagnostic technologies, advancements in drug delivery technology, progress in biomarker identification, the use of artificial intelligence in drug discovery, the development of next-generation sequencing technologies, and the creation of targeted gene therapies.

The growing emphasis on pediatric epilepsy is expected to significantly boost the growth of the Lennox-Gastaut syndrome drug market in the coming years. Pediatric epilepsy is a neurological condition marked by recurrent seizures in children, with its prevalence rising due to the increasing rates of neonatal and infant brain injuries, which can lead to the onset of epilepsy in early childhood. The focus on pediatric epilepsy reinforces the need for Lennox-Gastaut syndrome drugs by highlighting the importance of early intervention, as specialized medications are essential for managing hard-to-control seizures and preventing developmental delays in children with epilepsy. This underscores the demand for therapies tailored to address their specific neurological needs. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2021 and 2022, accounting for about 1% of the adult population in the United States. As a result, the rising attention on pediatric epilepsy is fueling the growth of the Lennox-Gastaut syndrome drug market.

Key players in the Lennox-Gastaut syndrome drug market are increasingly focusing on advancements in orphan drug designation to gain regulatory support, ensure market exclusivity, and expedite the commercialization of treatments for this rare and severe condition. Orphan drug designation is a special status granted by regulatory bodies, such as the FDA, to drugs developed for rare diseases or conditions that affect fewer than 200,000 individuals in a specific region. For example, in March 2023, Marinus Pharmaceuticals Inc., a U.S.-based pharmaceutical company, announced that the FDA had granted Orphan Drug Designation (ODD) to ganaxolone for treating Lennox-Gastaut syndrome (LGS). LGS is a severe form of epilepsy that begins in childhood and is marked by intractable seizures and neurodevelopmental impairment. This designation offers advantages including market exclusivity after regulatory approval, exemption from FDA application fees, and tax credits for eligible clinical trials.

In December 2024, H. Lundbeck A/S, a pharmaceutical company based in Denmark, acquired Longboard Pharmaceuticals for $2.6 billion. This acquisition expands Lundbeck's neurology and psychiatry portfolio by incorporating Longboard's promising pipeline of treatments for neurological diseases, including rare and orphan conditions. The move strengthens Lundbeck's position in the global market and enhances its research and development capabilities for central nervous system disorders. Longboard Pharmaceuticals Inc., a U.S.-based clinical-stage biopharmaceutical company, specializes in developing innovative, transformative medicines for Lennox-Gastaut syndrome.

Major players in the lennox-gastaut syndrome drug market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi SA, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, UCB SA, Eisai Co. Ltd., Amneal Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., Lundbeck A/S, GW Pharmaceuticals Plc, Ultragenyx Pharmaceutical Inc., Marinus Pharmaceuticals Inc., Stoke Therapeutics Inc., Zynerba Pharmaceuticals Inc., and Ovid Therapeutics Inc.

North America was the largest region in the lennox-gastaut syndrome drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lennox-gastaut syndrome drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lennox-gastaut syndrome drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lennox-gastaut syndrome (LGS) drug market consists of sales of corticosteroids, benzodiazepines, and sleep-inducing agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lennox-Gastaut Syndrome Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lennox-gastaut syndrome drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for lennox-gastaut syndrome drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lennox-gastaut syndrome drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Lennox-Gastaut Syndrome Drug Market Characteristics

3. Lennox-Gastaut Syndrome Drug Market Trends And Strategies

4. Lennox-Gastaut Syndrome Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lennox-Gastaut Syndrome Drug Growth Analysis And Strategic Analysis Framework

6. Lennox-Gastaut Syndrome Drug Market Segmentation

7. Lennox-Gastaut Syndrome Drug Market Regional And Country Analysis

8. Asia-Pacific Lennox-Gastaut Syndrome Drug Market

9. China Lennox-Gastaut Syndrome Drug Market

10. India Lennox-Gastaut Syndrome Drug Market

11. Japan Lennox-Gastaut Syndrome Drug Market

12. Australia Lennox-Gastaut Syndrome Drug Market

13. Indonesia Lennox-Gastaut Syndrome Drug Market

14. South Korea Lennox-Gastaut Syndrome Drug Market

15. Western Europe Lennox-Gastaut Syndrome Drug Market

16. UK Lennox-Gastaut Syndrome Drug Market

17. Germany Lennox-Gastaut Syndrome Drug Market

18. France Lennox-Gastaut Syndrome Drug Market

19. Italy Lennox-Gastaut Syndrome Drug Market

20. Spain Lennox-Gastaut Syndrome Drug Market

21. Eastern Europe Lennox-Gastaut Syndrome Drug Market

22. Russia Lennox-Gastaut Syndrome Drug Market

23. North America Lennox-Gastaut Syndrome Drug Market

24. USA Lennox-Gastaut Syndrome Drug Market

25. Canada Lennox-Gastaut Syndrome Drug Market

26. South America Lennox-Gastaut Syndrome Drug Market

27. Brazil Lennox-Gastaut Syndrome Drug Market

28. Middle East Lennox-Gastaut Syndrome Drug Market

29. Africa Lennox-Gastaut Syndrome Drug Market

30. Lennox-Gastaut Syndrome Drug Market Competitive Landscape And Company Profiles

31. Lennox-Gastaut Syndrome Drug Market Other Major And Innovative Companies

32. Global Lennox-Gastaut Syndrome Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lennox-Gastaut Syndrome Drug Market

34. Recent Developments In The Lennox-Gastaut Syndrome Drug Market

35. Lennox-Gastaut Syndrome Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기